These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31243222)

  • 1. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.
    Inomata S; Anan A; Yamauchi E; Yamauchi R; Kunimoto H; Takata K; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Irie M; Shakado S; Sohda T; Sakisaka S
    Intern Med; 2019 Oct; 58(20):2915-2922. PubMed ID: 31243222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Male-specific Association between Iron and Lipid Metabolism Changes and Erythroferrone after Hepatitis C Virus Eradication.
    Inomata S; Morihara D; Anan A; Yamauchi E; Yamauchi R; Takata K; Tanaka T; Yokoyama K; Takeyama Y; Irie M; Shakado S; Sohda T; Sakisaka S; Hirai F
    Intern Med; 2022 Feb; 61(4):461-467. PubMed ID: 34433710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease.
    Mangaonkar AA; Thawer F; Son J; Ajebo G; Xu H; Barrett NJ; Wells LG; Bowman L; Clair B; Patel N; Bora P; Jung G; Nemeth E; Kutlar A
    Br J Haematol; 2020 Jun; 189(6):1204-1209. PubMed ID: 32030737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
    Fujita N; Sugimoto R; Motonishi S; Tomosugi N; Tanaka H; Takeo M; Iwasa M; Kobayashi Y; Hayashi H; Kaito M; Takei Y
    J Hepatol; 2008 Nov; 49(5):702-10. PubMed ID: 18620776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients.
    El Said HW; Abou Seif KH; Ahmed YS; Abou Elleil HA; El Said TW; Behairy MA; Mohamed MM; Ahmed FA
    Nephrology (Carlton); 2018 Apr; 23(4):323-330. PubMed ID: 28130911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marathon Run-induced Changes in the Erythropoietin-Erythroferrone-Hepcidin Axis are Iron Dependent.
    Tomczyk M; Kortas J; Flis D; Kaczorowska-Hac B; Grzybkowska A; Borkowska A; Lewicka E; Dabrowska-Kugacka A; Antosiewicz J
    Int J Environ Res Public Health; 2020 Apr; 17(8):. PubMed ID: 32316587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.
    Fujita N; Sugimoto R; Takeo M; Urawa N; Mifuji R; Tanaka H; Kobayashi Y; Iwasa M; Watanabe S; Adachi Y; Kaito M
    Mol Med; 2007; 13(1-2):97-104. PubMed ID: 17515961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
    Pirotte M; Fillet M; Seidel L; Jaspers A; Baron F; Beguin Y
    Am J Hematol; 2021 Oct; 96(10):1275-1286. PubMed ID: 34310730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
    Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
    PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia.
    El-Gamal RAE; Abdel-Messih IY; Habashy DM; Zaiema SEG; Pessar SA
    Ann Hematol; 2020 Jan; 99(1):31-39. PubMed ID: 31834456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
    Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
    Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Erythroferrone, Hepcidin, and Iron Overload Status in Iraqi Transfusion-Dependent β-Thalassemia Major Patients.
    Smesam HNK; Albuthabhak HAQ; Arjmand S; Al-Hakeim HK; R Siadat SO
    Hemoglobin; 2020 Jul; 44(4):272-277. PubMed ID: 32718192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Sun HY; Cheng PN; Tseng CY; Tsai WJ; Chiu YC; Young KC
    Gut; 2018 Jul; 67(7):1342-1350. PubMed ID: 28615303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis.
    Valenti L; Pulixi EA; Arosio P; Cremonesi L; Biasiotto G; Dongiovanni P; Maggioni M; Fargion S; Fracanzani AL
    Haematologica; 2007 Aug; 92(8):1037-42. PubMed ID: 17640859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
    Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency.
    Foka P; Dimitriadis A; Karamichali E; Kyratzopoulou E; Giannimaras D; Koskinas J; Varaklioti A; Mamalaki A; Georgopoulou U
    Virulence; 2016 Aug; 7(6):679-90. PubMed ID: 27058404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.